Bristol Myers Squibb (CELG-RI) Free Cash Flow (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Free Cash Flow data on file, last reported at $757.0 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at $757.0 million, down 55.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.9 billion (down 9.0% YoY), and the FY2025 annual result was $12.8 billion, down 7.87% from the prior year.
• Free Cash Flow fell to $757.0 million in Q1 2026 per CELG-RI's latest filing, from $1.6 billion in the prior quarter.
• Over five years, Free Cash Flow peaked at $6.0 billion in Q3 2025 and troughed at $757.0 million in Q1 2026.
• A 5-year average of $3.1 billion and a median of $3.0 billion in 2022 frame the typical range for Free Cash Flow.
• On a YoY basis, Free Cash Flow climbed as much as 72.29% in 2025 and fell as far as 60.5% in 2025.
• A 5-year view of Free Cash Flow shows it stood at $3.0 billion in 2022, then jumped by 32.5% to $3.9 billion in 2023, then gained by 3.54% to $4.1 billion in 2024, then tumbled by 60.5% to $1.6 billion in 2025, then slumped by 52.81% to $757.0 million in 2026.
• Business Quant data shows CELG-RI's Free Cash Flow at $757.0 million in Q1 2026, $1.6 billion in Q4 2025, and $6.0 billion in Q3 2025.